Sa-β-galactosidase-based screening assay for the identification of senotherapeutic drugs

Heike Fuhrmann-Stroissnigg, Fernando E. Santiago, Diego Grassi, Yuan Yuan Ling, Laura J. Niedernhofer, Paul D. Robbins

Research output: Contribution to journalArticle

Abstract

Cell senescence is one of the hallmarks of aging known to negatively influence a healthy lifespan. Drugs able to kill senescent cells specifically in cell culture, termed senolytics, can reduce the senescent cell burden in vivo and extend healthspan. Multiple classes of senolytics have been identified to date including HSP90 inhibitors, Bcl-2 family inhibitors, piperlongumine, a FOXO4 inhibitory peptide and the combination of Dasatinib/Quercetin. Detection of SA-β-Gal at an increased lysosomal pH is one of the best characterized markers for the detection of senescent cells. Live cell measurements of senescence-associated β-galactosidase (SA-β-Gal) activity using the fluorescent substrate C12FDG in combination with the determination of the total cell number using a DNA intercalating Hoechst dye opens the possibility to screen for senotherapeutic drugs that either reduce overall SA-β-Gal activity by killing of senescent cells (senolytics) or by suppressing SA-β-Gal and other phenotypes of senescent cells (senomorphics). Use of a high content fluorescent image acquisition and analysis platform allows for the rapid, high throughput screening of drug libraries for effects on SA-β-Gal, cell morphology and cell number.

Original languageEnglish (US)
Article numbere58133
JournalJournal of Visualized Experiments
Volume2019
Issue number148
DOIs
StatePublished - Jun 2019

Fingerprint

Galactosidases
Assays
Screening
Pharmaceutical Preparations
Cell Aging
Cell Count
Image acquisition
Quercetin
Preclinical Drug Evaluations
Cell culture
Image analysis
Peptides
DNA
Coloring Agents
Dyes
Aging of materials
Libraries
Cells
Throughput
Cell Culture Techniques

Keywords

  • Aging
  • Biology
  • Cell Death
  • Cell Senescence
  • High Throughput Screening
  • Issue 148
  • Senescence Associated β-Galactosidase
  • Senolytics
  • Senomorphics
  • Senotherapeutics

PubMed: MeSH publication types

  • Journal Article
  • Video-Audio Media

Cite this

Sa-β-galactosidase-based screening assay for the identification of senotherapeutic drugs. / Fuhrmann-Stroissnigg, Heike; Santiago, Fernando E.; Grassi, Diego; Ling, Yuan Yuan; Niedernhofer, Laura J.; Robbins, Paul D.

In: Journal of Visualized Experiments, Vol. 2019, No. 148, e58133, 06.2019.

Research output: Contribution to journalArticle

Fuhrmann-Stroissnigg, Heike ; Santiago, Fernando E. ; Grassi, Diego ; Ling, Yuan Yuan ; Niedernhofer, Laura J. ; Robbins, Paul D. / Sa-β-galactosidase-based screening assay for the identification of senotherapeutic drugs. In: Journal of Visualized Experiments. 2019 ; Vol. 2019, No. 148.
@article{efb27847b9974da78ce536beb941b934,
title = "Sa-β-galactosidase-based screening assay for the identification of senotherapeutic drugs",
abstract = "Cell senescence is one of the hallmarks of aging known to negatively influence a healthy lifespan. Drugs able to kill senescent cells specifically in cell culture, termed senolytics, can reduce the senescent cell burden in vivo and extend healthspan. Multiple classes of senolytics have been identified to date including HSP90 inhibitors, Bcl-2 family inhibitors, piperlongumine, a FOXO4 inhibitory peptide and the combination of Dasatinib/Quercetin. Detection of SA-β-Gal at an increased lysosomal pH is one of the best characterized markers for the detection of senescent cells. Live cell measurements of senescence-associated β-galactosidase (SA-β-Gal) activity using the fluorescent substrate C12FDG in combination with the determination of the total cell number using a DNA intercalating Hoechst dye opens the possibility to screen for senotherapeutic drugs that either reduce overall SA-β-Gal activity by killing of senescent cells (senolytics) or by suppressing SA-β-Gal and other phenotypes of senescent cells (senomorphics). Use of a high content fluorescent image acquisition and analysis platform allows for the rapid, high throughput screening of drug libraries for effects on SA-β-Gal, cell morphology and cell number.",
keywords = "Aging, Biology, Cell Death, Cell Senescence, High Throughput Screening, Issue 148, Senescence Associated β-Galactosidase, Senolytics, Senomorphics, Senotherapeutics",
author = "Heike Fuhrmann-Stroissnigg and Santiago, {Fernando E.} and Diego Grassi and Ling, {Yuan Yuan} and Niedernhofer, {Laura J.} and Robbins, {Paul D.}",
year = "2019",
month = "6",
doi = "10.3791/58133",
language = "English (US)",
volume = "2019",
journal = "Journal of Visualized Experiments",
issn = "1940-087X",
publisher = "MYJoVE Corporation",
number = "148",

}

TY - JOUR

T1 - Sa-β-galactosidase-based screening assay for the identification of senotherapeutic drugs

AU - Fuhrmann-Stroissnigg, Heike

AU - Santiago, Fernando E.

AU - Grassi, Diego

AU - Ling, Yuan Yuan

AU - Niedernhofer, Laura J.

AU - Robbins, Paul D.

PY - 2019/6

Y1 - 2019/6

N2 - Cell senescence is one of the hallmarks of aging known to negatively influence a healthy lifespan. Drugs able to kill senescent cells specifically in cell culture, termed senolytics, can reduce the senescent cell burden in vivo and extend healthspan. Multiple classes of senolytics have been identified to date including HSP90 inhibitors, Bcl-2 family inhibitors, piperlongumine, a FOXO4 inhibitory peptide and the combination of Dasatinib/Quercetin. Detection of SA-β-Gal at an increased lysosomal pH is one of the best characterized markers for the detection of senescent cells. Live cell measurements of senescence-associated β-galactosidase (SA-β-Gal) activity using the fluorescent substrate C12FDG in combination with the determination of the total cell number using a DNA intercalating Hoechst dye opens the possibility to screen for senotherapeutic drugs that either reduce overall SA-β-Gal activity by killing of senescent cells (senolytics) or by suppressing SA-β-Gal and other phenotypes of senescent cells (senomorphics). Use of a high content fluorescent image acquisition and analysis platform allows for the rapid, high throughput screening of drug libraries for effects on SA-β-Gal, cell morphology and cell number.

AB - Cell senescence is one of the hallmarks of aging known to negatively influence a healthy lifespan. Drugs able to kill senescent cells specifically in cell culture, termed senolytics, can reduce the senescent cell burden in vivo and extend healthspan. Multiple classes of senolytics have been identified to date including HSP90 inhibitors, Bcl-2 family inhibitors, piperlongumine, a FOXO4 inhibitory peptide and the combination of Dasatinib/Quercetin. Detection of SA-β-Gal at an increased lysosomal pH is one of the best characterized markers for the detection of senescent cells. Live cell measurements of senescence-associated β-galactosidase (SA-β-Gal) activity using the fluorescent substrate C12FDG in combination with the determination of the total cell number using a DNA intercalating Hoechst dye opens the possibility to screen for senotherapeutic drugs that either reduce overall SA-β-Gal activity by killing of senescent cells (senolytics) or by suppressing SA-β-Gal and other phenotypes of senescent cells (senomorphics). Use of a high content fluorescent image acquisition and analysis platform allows for the rapid, high throughput screening of drug libraries for effects on SA-β-Gal, cell morphology and cell number.

KW - Aging

KW - Biology

KW - Cell Death

KW - Cell Senescence

KW - High Throughput Screening

KW - Issue 148

KW - Senescence Associated β-Galactosidase

KW - Senolytics

KW - Senomorphics

KW - Senotherapeutics

UR - http://www.scopus.com/inward/record.url?scp=85069807567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069807567&partnerID=8YFLogxK

U2 - 10.3791/58133

DO - 10.3791/58133

M3 - Article

C2 - 31305507

AN - SCOPUS:85069807567

VL - 2019

JO - Journal of Visualized Experiments

JF - Journal of Visualized Experiments

SN - 1940-087X

IS - 148

M1 - e58133

ER -